GlassScriptPhysician profile
Kayla Weaver
NPI 1003110081
$8,801.48
in general payments reported to CMS, 2019-2025
35 companies · $2,533 in 2025
The $2,533 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2022: $1,862 · 2023: $1,668 · 2024: $1,533 · 2025: $2,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,657 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,657.15 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,899.90 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,680.49 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $885.39 | 2021-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $532.58 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $490.57 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $339.51 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $277.23 | 2023-2025 | Dupixent |
| Genzyme Corporation | $262.60 | 2022-2025 | |
| Ardelyx, INC. | $236.83 | 2022-2025 | Ibsrela |
| Pfizer INC. | $228.74 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $222.31 | 2021-2024 | Ocaliva |
| Janssen Scientific Affairs, LLC | $207.93 | 2022-2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $205.85 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $172.53 | 2024-2025 | Omvoh, Zepbound |
| Gilead Sciences, INC. | $115.62 | 2021-2023 | Epclusa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $114.22 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $100.53 | 2021-2023 | Dificid |
| Vivus LLC | $93.30 | 2022-2025 | Pancreaze |
| Phathom Pharmaceuticals, INC. | $91.27 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $91.07 | 2021 | |
| Ferring Pharmaceuticals INC. | $68.66 | 2021-2022 | |
| Madrigal Pharmaceuticals | $61.47 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $54.51 | 2021-2023 | Linzess |
| Organon LLC | $53.91 | 2022-2025 | Hadlima |
| Amgen INC. | $46.09 | 2023 | Avsola, Amjevita |
| Celltrion USA INC. | $43.36 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $39.33 | 2021-2024 | |
| Exact Sciences Corporation | $32.05 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Braintree Laboratories, INC. | $29.71 | 2021-2023 | Suflave |
| Ethicon US, LLC | $29.54 | 2022 | |
| Intra-Sana Laboratories | $24.59 | 2021-2022 | |
| Sandoz INC. | $23.16 | 2024 | Hyrimoz |
| Aimmune Therapeutics, INC. | $17.71 | 2025 | Zenpep |
| Redhill Biopharma INC. | $17.68 | 2021 | |
| Alnylam Pharmaceuticals INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.